{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Exelixis, Inc."},"Symbol":{"label":"Symbol","value":"EXEL"},"Address":{"label":"Address","value":"1851 HARBOR BAY PARKWAY, ALAMEDA, California, 94502, United States"},"Phone":{"label":"Phone","value":"+1 650 837-7000"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma."},"CompanyUrl":{"label":"Company Url","value":"https://www.exelixis.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Amy C. Peterson","title":"Chief Medical Officer & Executive Vice President"},{"name":"Dana T. Aftab","title":"Chief Scientific Officer & Executive VP-Discovery"},{"name":"Michael M. Morrissey","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}